Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 4/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.41 |
| ▸ | QPCTL | Q9NXS2 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.40 |
| ▸ | SMO | Q99835 | 1/20 | 0.40 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.39 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28174136 | 0.75 | SOS1 (0.47) | P2RX7KMT2ACYP11B1CYP11B2 | |
| SCHEMBL417817 | 0.73 | KMT2A (0.42) | OPRD1CACNA1HHSP90AA1HSP90AB1SMO | |
| SCHEMBL3593918 | 0.73 | P2RX7 (0.78) | P2RX7 | |
| SCHEMBL415764 | 0.72 | RIPK3 (0.45) | CACNA1HHSP90AA1HSP90AB1SMORIPK3 | |
| SCHEMBL12841486 | 0.71 | P2RX7 (0.59) | P2RX7QPCTLCYP11B1CYP11B2 | |
| SCHEMBL14476844 | 0.70 | P2RX7 (0.54) | P2RX7QPCTL | |
| SCHEMBL2398286 | 0.70 | QPCTL (0.62) | P2RX7QPCTLKMT2A | |
| SCHEMBL12245404 | 0.70 | OPRD1 (0.51) | OPRD1 | |
| SCHEMBL28174173 | 0.69 | RAB9A (0.46) | P2RX7CYP11B1CYP11B2 | |
| SCHEMBL14203996 | 0.68 | CYP11B2 (0.44) | P2RX7KMT2ACYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022083-A1 | SMALL MOLECULE MODULATORS OF CELL ADHESION | ADHEREX TECHNOLOGIES, INC. (CA) | 2012-01-26 | — | — | US | disclosed |
| US-20090291967-A1 | SMALL MOLECULE MODULATORS OF CELL ADHESION | ADHEREX TECHNOLOGIES, INC. (CA) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291967-A1 | SMALL MOLECULE MODULATORS OF CELL ADHESION | CDH1, EPCAM, ICAM1 | P2RX7 3474/4885OPRD1 1859/4885CACNA1H 1109/4885 |
| US-20120022083-A1 | SMALL MOLECULE MODULATORS OF CELL ADHESION | CDH1, EPCAM, ICAM1 | P2RX7 3474/4885OPRD1 1859/4885CACNA1H 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.